Bishal Gyawali, MD, PhD, is a medical oncologist and an associate professor in medical oncology and public health sciences and scientist in the Division of Cancer Care and Epidemiology, in Queen’s University, Kingston, Canada. His clinical expertise is across multiple adult solid tumors, with special focus on GI, GU and breast malignancies. He is in the editorial and advisory board for multiple medicine and oncology journals and has authored or co-authored more than 200 peer-reviewed articles in high-impact journals. Dr. Gyawali’s areas of academic interests include cancer policy, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, supportive care, cancer care disparities, and global oncology. He introduced the term “cancer groundshot” advocating for investments in implementation of proven interventions for global cancer control. He is the co-leader of the Common Sense Oncology movement, working to ensure cancer research and policy is aligned with the goal of improving outcomes that matter to patients. His interviews and studies have been reported in several influential media such as CNN, NPR, Washington Post, STAT News etc. He is an expert for the WHO Drug Advisory Panel. He is a member of the WHO Essential Medicines List Committee for cancer drugs; ESMO-MCBS, ESMO Communications, and ESMO Public Policy committees, and ASCO-Health Equity and Outcomes Committee.
October 24, 2023
October 18, 2023
Dr. Gyawali was announced as one of the members of the ESMO 2023 Social Media Ambassadors team.
October 11, 2023
Sangam Shah announced as the winner of the inaugural Anita Gyawali-Ganesh Gyawali Health Research Award.
June 29, 2023
New Medscape blog post – “At ASCO, the Cancer Community Hyped the Wrong Trial“.
June 7, 2023
Dr. Gyawali was appointed as a member of the editorial board of BMJ Oncology.
June 2-6, 2023
Dr. Gyawali attended ASCO 2023 in Chicago. Click here to view his interview highlighting presentations of interest.
June 1, 2023
New Medscape blog post – “What’s Wrong With Cancer Clinical Trials? Look at Olaparib.”
May 31, 2023
“Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study” released in The Lancet Oncology.
May 12, 2023
Dr. Gyawali’s column, Racism in Medicine, received a 2023 AZBEE National Gold Award.
May 9, 2023
Dr. Gyawali spoke at the Oncology Grand Rounds in London, Ontario CAN, “Common Sense in Oncology: How Not to be Misled by Headlines or Editorials”.
April 26, 2023
New Medscape blog post – “The CodeBreaK Trial: We Broke the Code in More Ways Than One.